| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4765190
Max Phase: Preclinical
Molecular Formula: C31H33F3N4O6
Molecular Weight: 614.62
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(=O)N[C@@H](COCc1ccccc1)C(=O)N[C@H](CCc1ccccc1)C(=O)N[C@H](Cc1ccc(F)c(F)c1F)C(=O)NO
Standard InChI: InChI=1S/C31H33F3N4O6/c1-19(39)35-26(18-44-17-21-10-6-3-7-11-21)30(41)36-24(15-12-20-8-4-2-5-9-20)29(40)37-25(31(42)38-43)16-22-13-14-23(32)28(34)27(22)33/h2-11,13-14,24-26,43H,12,15-18H2,1H3,(H,35,39)(H,36,41)(H,37,40)(H,38,42)/t24-,25-,26+/m1/s1
Standard InChI Key: FSGOFTQPNYNSIT-CYXNTTPDSA-N
Associated Targets(Human)
Matrix metalloproteinase 12 1130 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 614.62 | Molecular Weight (Monoisotopic): 614.2352 | AlogP: 2.48 | #Rotatable Bonds: 15 |
| Polar Surface Area: 145.86 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 5 |
| #RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 8.72 | CX Basic pKa: | CX LogP: 2.86 | CX LogD: 2.84 |
| Aromatic Rings: 3 | Heavy Atoms: 44 | QED Weighted: 0.10 | Np Likeness Score: -0.34 |
References
| 1. Baggio C,Velazquez JV,Fragai M,Nordgren TM,Pellecchia M. (2020) Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease., 63 (21): [PMID:33107733] [10.1021/acs.jmedchem.0c01285] |
Source
Source(1):